Anthera Pharmaceuticals sees high trading volumes, stock price drops 53%
Today, Anthera Pharmaceuticals (ANTH) registered a stock price decline of ~53% on news that the stock will be suspended from trading on the NASDAQ Capital Market at the start of business tomorrow. ANTH stock traded at a 52-week low on the day. The company has two candidates in its product pipeline, as the image below shows.
Following the delisting, Anthera Pharmaceuticals’ securities will be listed on the OTC Market. If the company requires its stock to trade on another trading platform, it may take the necessary steps.
On May 22, NASDAQ informed Anthera Pharmaceuticals that it had failed to meet some continued listing requirements. These requirements include the minimum bid price requirement pursuant to Listing Rule 5550(a)(2). In the most recent quarterly filings from the company with the SEC, it disclosed that it has begun to wind down its operations and suspended all its clinical development activities as it explores strategic merger or acquisition options.
Anthera Pharmaceuticals withdraws its appeal for a hearing related to delisting its shares
On May 29, Anthera Pharmaceuticals had appealed the delisting determination and was granted a hearing with the NASDAQ Hearings Panel. The hearing was scheduled for tomorrow. However, the company withdrew from the hearing today, as it hasn’t been able to meet the listing requirements and doesn’t expect to be able to in the near future. So, as per Anthera Pharmaceuticals, the company’s board of directors deemed the withdrawal from the hearing in the company’s best interest.
The factors considered by the board of directors include “the Board’s assessment of the probability of entering into a definitive agreement to transact the Company in the imminent future, the probability of securing shareholder approval for a reverse stock split, and an analysis of the benefits of continued listing.” These factors, however, weighed against the continued listing regulatory requirements and costs.
Today, Aquinox (AQXP) announced that its late-stage investigational drug, the once-daily oral therapy rosiptor, failed to demonstrate a statistically significant benefit over placebo for interstitial cystitis or bladder pain syndrome.
Cleveland-Cliffs (CLF) is expected to report its first-quarter earnings results on April 25.
While the overall cannabis sector experienced weakness on April 23, some stocks managed to gain some positive momentum in the first half of the day.
After being listed on the NASDAQ (QQQ) on March 29, Lyft (LYFT) stock has traded on a negative note so far.
Coca-Cola (KO) impressed investors with better-than-expected revenue and earnings for the first quarter.
Microsoft (MSFT) announced this month that it had acquired a San Diego startup called Express Logic for an undisclosed amount.
Spirit Airlines is scheduled to report its first-quarter results on April 25. The airline has an impressive record of beating earnings estimates.